[China Packaging Network News] Now there are still many problems in China's packaging design market, many companies do not pay special attention to the packaging design of drugs in the promotion and marketing of products, which has led to the disadvantages of China's packaging design. However, there are still many solutions. We firmly believe that as China's packaging design market continues to improve, we will have more progress.
1. It should be emphasized that packaging materials and containers that come into direct contact with drugs are an integral part of the drug. In particular, preparations for large infusions, needles, aerosols, capsules, etc., have different packaging materials, formulation formulas for containers, different raw and auxiliary materials selected, and different production processes, and some may be dissolved or interact with drugs. Or long-term immersion corrosion stripping drugs directly affect the quality of drugs. Moreover, some have hidden dangers to the quality of medicines and human body. For example, ampoules and infusion bottles (bags), if not for different drugs using different formulations and production processes, there will often be dissolved and glass stripping phenomenon, generally can not be found in the routine drug test, the dissolution of natural rubber stopper in the opposite sex protein May be a source of heat, dissolved pyridine compounds are a positive factor in carcinogenic, teratogenic, mutagenic, and subtle glass removal is blocked blood vessel thrombosis or lung granuloma, and so on. On the other hand, due to the variety of drugs and the complex active active groups, the requirements for the packaging materials and containers in direct contact with them are much higher than for other products.
2. China's pharmaceutical packaging companies and drug packaging products are relatively backward, the overall level of pharmaceutical packaging is low, and the contribution of packaging to the development of pharmaceutical economy is low. Although there are about 1,000 existing enterprises in China, direct contact is made with the production of more than 60 varieties of five major categories such as pharmaceutical glass, metal, medicinal gelatin products, rubber, plastics (containers, sheets, films) and composite sheets (films). Drug packaging materials and containers have an annual output value of about 15 billion yuan. However, at present, the overall level of pharmaceutical packaging in China lags behind that of developed countries. The quality of packaging, the quality of packaging materials, and the contribution of packaging to the pharmaceutical economy are all significantly lower than those of developed countries. Among the existing pharmaceutical packaging materials manufacturing enterprises, many are township collective enterprises, with small scales, low quality of personnel, equipment, technology and management, and unstable product quality. For a long time, China has not set up a regulatory system and an access system for imported pharmaceutical packaging materials. At the same time, in actual work, it is also found that some imported products have unstable quality. In particular, after the entry into the WTO, the import of pharmaceutical packaging materials may have a significant increase. In order to ensure good quality and treat the same treatment for domestic and foreign companies, it is also necessary to set up access procedures for imported pharmaceutical packaging products. It is recommended that the competent government departments issue relevant guidelines and policies for optimizing the organizational structure, corporate structure and product structure of the pharmaceutical packaging industry in China, rationally allocate resources, and fundamentally improve the overall level of the pharmaceutical packaging industry in China.
3. Internationally, drug regulatory authorities in various countries have attached great importance to supervision and supervision of pharmaceutical packaging and drug packaging materials. However, due to the lack of legal basis, supervision of pharmaceutical packaging materials in China is insufficient. Therefore, the quality of low-quality, non-standard drug packaging products are common; the use of unqualified drug packaging products or the use of unapproved drug packaging materials has not been resolved; the promotion and application of excellent new drug packaging materials products is slow, and some are backward and inconvenient to use. Even drug packaging materials that affect the quality of drugs are difficult to eliminate, and some still affect the quality of drugs. Therefore, in order to improve the quality of packaging materials and containers that are in direct contact with pharmaceuticals in order to improve the quality of packaging materials and containers that are in direct contact with medicines, ensure the safety and effectiveness of medicines and promote the healthy development of the pharmaceutical economy, we must strengthen the supervision and management of these products and their use, and take effective measures. The Drug Administration Act made explicit requirements. Drug regulatory authorities must organize, approve, and promulgate drug and packaging materials standards from the perspective of meeting the requirements of pharmaceuticals to ensure human health and safety. The standards should include three aspects: product quality, inspection and testing methods, and quality assurance system. When approving a new drug, the packaging material of the new drug is also approved and the safety compatibility information of the packaging material and the drug is reviewed.
After reading the above knowledge, I believe we can see more hope in the future of packaging design. In fact, any food in the process of development will have many problems. We should have full confidence in the future before we can achieve more in packaging design. For more information, you are welcome to continue to pay attention to China Packaging Network!
